Science Explorer Back to mapMap
Discussion
Researcher · Abbott Fund · United States

Jonathan A. Meulbroek

Jonathan A. Meulbroek publishes mostly in Molecular Biology, Oncology and Immunology, on topics such as Advanced Drug Delivery Systems, Cancer therapeutics and mechanisms and HER2/EGFR in Cancer Research.

ORCID 0009-0000-5322-2844 OpenAlex
World rank
#911,290
of 7,710,434 ranked researchers
Rank in United States
#300,242
of 1,627,098
Works
71
Citations
3.3k
Citations per work
46.5
h-index
18
i10-index 18Top 39% in Molecular Biology
Jonathan A. Meulbroek

What does Jonathan A. Meulbroek research?

Jonathan A. Meulbroek's work is mostly in Medicine (30%), Biochemistry, Genetics and Molecular Biology (15%), Immunology and Microbiology (10%).

Everything else: 32 works · 45.0% of their workHealth Sciences: 21 works · 30.2% of their workMedicine: 21 works · 30.2% of their workOncology: 7 works · 9.7% of their workRadiology, Nuclear Medicine and Imaging: 5 works · 7.5% of their workEpidemiology: 5 works · 6.5% of their workGenetics: 5 works · 6.5% of their workLife Sciences: 18 works · 24.8% of their workBiochemistry, Genetics and Molecular Biology: 11 works · 15.1% of their workMolecular Biology: 11 works · 15.1% of their workImmunology and Microbiology: 7 works · 9.7% of their workImmunology: 7 works · 9.7% of their workTHEIR WORKJonathan A.Meulbroek71works
Life Sciences25%Health Sciences30%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else3245.0%
    1. Medicine2130.2%
    1. Biochemistry, Genetics and Molecular Biology1115.1%
    2. Immunology and Microbiology79.7%
  1. 1Molecular Biology15% of their works
  2. 2Oncology10% of their works
  3. 3Immunology10% of their works
  4. 4Radiology, Nuclear Medicine and Imaging8% of their works
  5. 5Genetics6% of their works
  6. 6Epidemiology6% of their works

Research topics

Which keywords describe Jonathan A. Meulbroek's research?

The keywords of their largest research topics: Chemotherapy, Chitosan, Nanoparticles, Breast Cancer, DNA, Fc Receptors, HER2 and Therapeutic Antibodies.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Chemotherapy82 topics
  2. Chitosan51 topic
  3. Nanoparticles51 topic
  4. Breast Cancer41 topic
  5. DNA41 topic
  6. Fc Receptors41 topic
  7. HER241 topic
  8. Therapeutic Antibodies41 topic
  9. Topoisomerases41 topic
  10. Chronic Lymphocytic Leukemia31 topic
  11. Community-Acquired Pneumonia31 topic
  12. Dendritic Cells31 topic
  13. Genomic Aberrations31 topic
  14. Immunity31 topic
  15. Pneumococcal Conjugate Vaccine31 topic
  16. Antibiotic Resistance21 topic
  17. Multidrug-Resistant Bacteria21 topic

Where does Jonathan A. Meulbroek work?

Jonathan A. Meulbroek's main affiliation in the publication record is Abbott Fund, United States.

How many publications and citations does Jonathan A. Meulbroek have?

OpenAlex counts 71 works and 3,303 citations for Jonathan A. Meulbroek, an h-index of 18, ranking #911,290 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Jonathan A. Meulbroek. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.